Kcna3
protein-coding gene in the species Rattus norvegicus
≈ 3 min read
Names in other languages
- DeutschKcna3
- EnglishKcna3
- EspañolKcna3
- FrançaisKcna3
- NederlandsKcna3
- PortuguêsKcna3
- srnKcna3
- SvenskaKcna3
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Potassium voltage-gated channel, shaker-related subfamily, member 3, also known as KCNA3 or K v 1.3, is a protein that in humans is encoded by the KCNA3 gene. Potassium channels represent the most complex class of voltage-gated ion channels from both functional and structural standpoints.
Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes – shaker, shaw, shab, and shal – have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily.
This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, members of which allow nerve cells to efficiently repolarize following an action potential. It plays an essential role in T cell proliferation and activation.
This gene appears to be intronless and is clustered together with KCNA2 and KCNA10 genes on chromosome 1.
Blockers
K v 1.3 is blocked by several peptides from venomous creatures including scorpions (ADWX1, OSK1, margatoxin, kaliotoxin, charybdotoxin, noxiustoxin, anuroctoxin, OdK2 ) and sea anemone (ShK, ShK-F6CA, ShK-186, ShK-192, BgK ), and by small molecule compounds (e.g., PAP-1, Psora-4, correolide, benzamides, CP339818, progesterone and the anti-lepromatous drug clofazimine ). The K v 1.3 blocker clofazimine has been reported to be effective in the treatment of chronic graft-versus-host disease, cutaneous lupus, and pustular psoriasis in humans.
Furthermore, clofazimine in combination with the antibiotics clarithromycin and rifabutin induced remission for about 2 years in patients with Crohn's disease, but the effect was temporary; the effect was thought to be due to anti-mycobacterial activity, but could well have been an immunomodulatory effect by clofazimine.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378328034 under CC BY-SA 4.0; modifications have been made.